• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

针对关切的 SARS-CoV-2 变异株的免疫的记忆体液相关性。

Anamnestic humoral correlates of immunity across SARS-CoV-2 variants of concern.

机构信息

Ragon Institute of MGH, MIT, and Harvard , Cambridge, Massachusetts, USA.

Department of Medicine, Massachusetts General Hospital , Boston, Massachusetts, USA.

出版信息

mBio. 2023 Aug 31;14(4):e0090223. doi: 10.1128/mbio.00902-23. Epub 2023 Aug 3.

DOI:10.1128/mbio.00902-23
PMID:37535402
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10470538/
Abstract

While immune correlates against SARS-CoV-2 are typically defined at peak immunogenicity following vaccination, immunologic responses that expand selectively during the anamnestic response following infection can provide mechanistic and detailed insights into the immune mechanisms of protection. Moreover, whether anamnestic correlates are conserved across variants of concern (VOC), including the Delta and more distant Omicron VOC, remains unclear. To define the anamnestic correlates of immunity, across VOCs, we deeply profiled the humoral immune response in individuals infected with sequence-confirmed Delta or Omicron VOC after completing the vaccination series. While limited acute N-terminal domain and receptor-binding domain (RBD)-specific immune expansion was observed following breakthrough infection, a significant immunodominant expansion of opsonophagocytic Spike-specific antibody responses focused largely on the conserved S2-domain of SARS-CoV-2 was observed. This S2-specific functional humoral response continued to evolve over 2-3 weeks following Delta or Omicron breakthrough, targeting multiple VOCs and common coronaviruses. Strong responses were observed on the fusion peptide (FP) region and the heptad repeat 1 (HR1) region adjacent to the RBD. Notably, the FP is highly conserved across SARS-related coronaviruses and even non-SARS-related betacoronavirus. Taken together, our results point to a critical role of highly conserved, functional S2-specific responses in the anamnestic antibody response to SARS-CoV-2 infection across VOCs. These humoral responses linked to virus clearance can guide next-generation vaccine-boosting approaches to confer broad protection against future SARS-related coronaviruses. IMPORTANCE The Spike protein of SARS-CoV-2 is the primary target of antibody-based recognition. Selective pressures, be it the adaption to human-to-human transmission or evasion of previously acquired immunity, have spurred the emergence of variants of the virus such as the Delta and Omicron lineages. Therefore, understanding how antibody responses are expanded in breakthrough cases of previously vaccinated individuals can provide insights into key correlates of protection against current and future variants. Here, we show that vaccinated individuals who had documented COVID-19 breakthrough showed anamnestic antibody expansions targeting the conserved S2 subdomain of Spike, particularly within the fusion peptide region. These S2-directed antibodies were highly leveraged for non-neutralizing, phagocytic functions and were similarly expanded independent of the variant. We propose that through deep profiling of anamnestic antibody responses in breakthrough cases, we can identify antigen targets susceptible to novel monoclonal antibody therapy or vaccination-boosting strategies.

摘要

虽然针对 SARS-CoV-2 的免疫相关性通常在接种疫苗后的免疫高峰期定义,但感染后记忆应答中选择性扩增的免疫反应可以为保护的免疫机制提供机制和详细的见解。此外,记忆相关性是否在关注的变体(VOC)中保持一致,包括 Delta 和更远的 Omicron VOC,仍然不清楚。为了定义跨 VOC 的免疫记忆相关性,我们在完成疫苗接种系列后,对确诊为 Delta 或 Omicron VOC 感染的个体的体液免疫反应进行了深入分析。虽然在突破性感染后观察到有限的急性 N 端结构域和受体结合域(RBD)特异性免疫扩张,但观察到针对 SARS-CoV-2 的保守 S2 结构域的显著免疫优势扩展的调理吞噬性 Spike 特异性抗体反应。这种 S2 特异性功能性体液反应在 Delta 或 Omicron 突破后继续进化 2-3 周,针对多个 VOC 和常见冠状病毒。在融合肽(FP)区域和紧邻 RBD 的七肽重复 1(HR1)区域观察到强烈的反应。值得注意的是,FP 在 SARS 相关冠状病毒甚至非 SARS 相关贝塔冠状病毒中高度保守。总之,我们的结果表明,在跨 VOC 的 SARS-CoV-2 感染的记忆抗体反应中,高度保守、功能性的 S2 特异性反应起着关键作用。这些与病毒清除相关的体液反应可以指导下一代疫苗增强方法,为未来的 SARS 相关冠状病毒提供广泛的保护。重要性 SARS-CoV-2 的 Spike 蛋白是基于抗体的识别的主要靶标。无论是适应人与人之间的传播还是逃避先前获得的免疫,选择压力都促使病毒出现了变异,如 Delta 和 Omicron 谱系。因此,了解接种疫苗的个体在突破性病例中抗体反应如何扩张,可以深入了解针对当前和未来变异体的关键保护相关性。在这里,我们表明,有记录的 COVID-19 突破性病例的接种个体显示出针对 Spike 的保守 S2 亚结构域的记忆性抗体扩张,特别是在融合肽区域内。这些针对 S2 的抗体被高度用于非中和的吞噬功能,并且在变体上同样扩张。我们提出,通过对突破性病例的记忆性抗体反应进行深入分析,我们可以确定易受新型单克隆抗体治疗或疫苗增强策略影响的抗原靶标。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f9f1/10470538/3dee36d367a9/mbio.00902-23.f006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f9f1/10470538/7be78e853aff/mbio.00902-23.f001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f9f1/10470538/e37fab2fa21a/mbio.00902-23.f002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f9f1/10470538/5f138eca8214/mbio.00902-23.f003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f9f1/10470538/0a5966d72c18/mbio.00902-23.f004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f9f1/10470538/b79e505e8d9c/mbio.00902-23.f005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f9f1/10470538/3dee36d367a9/mbio.00902-23.f006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f9f1/10470538/7be78e853aff/mbio.00902-23.f001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f9f1/10470538/e37fab2fa21a/mbio.00902-23.f002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f9f1/10470538/5f138eca8214/mbio.00902-23.f003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f9f1/10470538/0a5966d72c18/mbio.00902-23.f004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f9f1/10470538/b79e505e8d9c/mbio.00902-23.f005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f9f1/10470538/3dee36d367a9/mbio.00902-23.f006.jpg

相似文献

1
Anamnestic humoral correlates of immunity across SARS-CoV-2 variants of concern.针对关切的 SARS-CoV-2 变异株的免疫的记忆体液相关性。
mBio. 2023 Aug 31;14(4):e0090223. doi: 10.1128/mbio.00902-23. Epub 2023 Aug 3.
2
A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.一种基于三聚体 RBD 的马赛克型 COVID-19 疫苗候选物可诱导针对奥密克戎和其他 SARS-CoV-2 变体的强大中和作用。
Elife. 2022 Aug 25;11:e78633. doi: 10.7554/eLife.78633.
3
Wild-type SARS-CoV-2 neutralizing immunity decreases across variants and over time but correlates well with diagnostic testing.野生型 SARS-CoV-2 中和抗体的免疫活性会随着时间推移和变异株的不同而降低,但与诊断检测有很好的相关性。
Front Immunol. 2023 Feb 8;14:1055429. doi: 10.3389/fimmu.2023.1055429. eCollection 2023.
4
Hybrid Immunity Shifts the Fc-Effector Quality of SARS-CoV-2 mRNA Vaccine-Induced Immunity.杂合免疫改变了 SARS-CoV-2 mRNA 疫苗诱导免疫的 Fc 效应子质量。
mBio. 2022 Oct 26;13(5):e0164722. doi: 10.1128/mbio.01647-22. Epub 2022 Aug 24.
5
A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern.一种靶向 RBD 和 S2 的双特异性抗体能有效中和 SARS-CoV-2 奥密克戎及其他关注变异株。
J Virol. 2022 Aug 24;96(16):e0077522. doi: 10.1128/jvi.00775-22. Epub 2022 Aug 2.
6
Pre-Omicron Vaccine Breakthrough Infection Induces Superior Cross-Neutralization against SARS-CoV-2 Omicron BA.1 Compared to Infection Alone.奥密克戎变异株疫苗突破性感染诱导针对 SARS-CoV-2 奥密克戎 BA.1 的交叉中和反应优于单独感染。
Int J Mol Sci. 2022 Jul 12;23(14):7675. doi: 10.3390/ijms23147675.
7
Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.全面描述了针对 SARS-CoV-2 刺突蛋白的抗体反应,发现了除轻度感染诱导的表位之外的其他疫苗诱导的表位。
Elife. 2022 Jan 24;11:e73490. doi: 10.7554/eLife.73490.
8
Boosting with Multiple Doses of mRNA Vaccine after Priming with Two Doses of Protein Subunit Vaccine MVC-COV1901 Elicited Robust Humoral and Cellular Immune Responses against Emerging SARS-CoV-2 Variants.两剂蛋白亚单位疫苗 MVC-COV1901 初免后加强接种多剂 mRNA 疫苗可增强针对新型 SARS-CoV-2 变异株的体液和细胞免疫应答。
Microbiol Spectr. 2022 Oct 26;10(5):e0060922. doi: 10.1128/spectrum.00609-22. Epub 2022 Aug 25.
9
Distinct features of SARS-CoV-2 humoral immunity against Omicron breakthrough infection.奥密克戎突破性感染中针对 SARS-CoV-2 体液免疫的独特特征。
Vaccine. 2023 Nov 13;41(47):7019-7025. doi: 10.1016/j.vaccine.2023.10.035. Epub 2023 Oct 17.
10
SARS-CoV-2 Infection-and mRNA Vaccine-induced Humoral Immunity among Schoolchildren in Hawassa, Ethiopia.埃塞俄比亚霍瓦萨地区学龄儿童中的 SARS-CoV-2 感染和 mRNA 疫苗诱导的体液免疫。
Front Immunol. 2023 Jun 15;14:1163688. doi: 10.3389/fimmu.2023.1163688. eCollection 2023.

引用本文的文献

1
Adenovectored RSV prefusion glycoprotein + soluble glycoprotein combination immunization establishes persistent opsonophagocytic antibody response through IgG3.腺病毒载体呼吸道合胞病毒预融合糖蛋白+可溶性糖蛋白联合免疫通过IgG3建立持续的调理吞噬抗体反应。
Front Immunol. 2025 Jul 22;16:1609779. doi: 10.3389/fimmu.2025.1609779. eCollection 2025.
2
Acute infectious mononucleosis generates persistent, functional EBNA-1 antibodies with high cross-reactivity to alpha-crystalline beta.急性传染性单核细胞增多症会产生对α-晶状体蛋白β具有高交叉反应性的持久性功能性EBNA-1抗体。
Cell Rep. 2025 May 27;44(5):115709. doi: 10.1016/j.celrep.2025.115709. Epub 2025 May 13.
3

本文引用的文献

1
Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause deadly disease.广谱中和抗 S2 抗体可预防三种导致致命疾病的人类β冠状病毒。
Immunity. 2023 Mar 14;56(3):669-686.e7. doi: 10.1016/j.immuni.2023.02.005. Epub 2023 Feb 16.
2
A Covid-19 Milestone Attained - A Correlate of Protection for Vaccines.新冠疫情的一个里程碑达成——疫苗保护的一个相关因素。
N Engl J Med. 2022 Dec 15;387(24):2203-2206. doi: 10.1056/NEJMp2211314. Epub 2022 Dec 10.
3
SARS-CoV-2 S2-targeted vaccination elicits broadly neutralizing antibodies.
Preclinical development of a replication-competent vesicular stomatitis virus-based Lassa virus vaccine candidate advanced into human clinical trials.
一种具有复制能力的基于水疱性口炎病毒的拉沙病毒候选疫苗的临床前开发已推进到人体临床试验阶段。
EBioMedicine. 2025 Apr;114:105647. doi: 10.1016/j.ebiom.2025.105647. Epub 2025 Mar 28.
4
Dose-dependent serological profiling of AdCLD-CoV19-1 vaccine in adults.成人中AdCLD-CoV19-1疫苗的剂量依赖性血清学分析
mSphere. 2025 Jan 28;10(1):e0099824. doi: 10.1128/msphere.00998-24. Epub 2024 Dec 26.
5
Transforming vaccinology.疫苗学的变革。
Cell. 2024 Sep 19;187(19):5171-5194. doi: 10.1016/j.cell.2024.07.021.
6
Compartment-specific antibody correlates of protection to SARS-CoV-2 Omicron in macaques.猕猴中针对新冠病毒奥密克戎毒株的组织特异性抗体保护相关性
iScience. 2024 Jun 4;27(9):110174. doi: 10.1016/j.isci.2024.110174. eCollection 2024 Sep 20.
7
Antibody-mediated control mechanisms of viral infections.病毒感染的抗体介导控制机制。
Immunol Rev. 2024 Nov;328(1):205-220. doi: 10.1111/imr.13383. Epub 2024 Aug 20.
8
Concurrent Administration of COVID-19 and Influenza Vaccines Enhances Spike-Specific Antibody Responses.同时接种新冠疫苗和流感疫苗可增强刺突蛋白特异性抗体反应。
Open Forum Infect Dis. 2024 Mar 13;11(4):ofae144. doi: 10.1093/ofid/ofae144. eCollection 2024 Apr.
9
Distinct Functional Humoral Immune Responses Are Induced after Live Attenuated and Inactivated Seasonal Influenza Vaccination.活疫苗和灭活疫苗接种后诱导了不同的功能性体液免疫应答。
J Immunol. 2024 Jan 1;212(1):24-34. doi: 10.4049/jimmunol.2200956.
10
Cytotoxic T Cells Targeting Spike Glycoprotein Are Associated with Hybrid Immunity to SARS-CoV-2.靶向刺突糖蛋白的细胞毒性 T 细胞与 SARS-CoV-2 的混合免疫有关。
J Immunol. 2023 May 1;210(9):1236-1246. doi: 10.4049/jimmunol.2200815.
SARS-CoV-2 S2 靶向疫苗接种可诱导广泛中和抗体。
Sci Transl Med. 2022 Jul 27;14(655):eabn3715. doi: 10.1126/scitranslmed.abn3715.
4
ACE2-binding exposes the SARS-CoV-2 fusion peptide to broadly neutralizing coronavirus antibodies.ACE2 结合暴露了 SARS-CoV-2 的融合肽,使其能够被广泛中和冠状病毒的抗体识别。
Science. 2022 Aug 12;377(6607):735-742. doi: 10.1126/science.abq2679. Epub 2022 Jul 12.
5
Broadly neutralizing antibodies target the coronavirus fusion peptide.广泛中和抗体靶向冠状病毒融合肽。
Science. 2022 Aug 12;377(6607):728-735. doi: 10.1126/science.abq3773. Epub 2022 Jul 12.
6
Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study.比较分析英国住院和死亡风险与 SARS-CoV-2 奥密克戎(B.1.1.529)和德尔塔(B.1.617.2)变异株的关系:一项队列研究。
Lancet. 2022 Apr 2;399(10332):1303-1312. doi: 10.1016/S0140-6736(22)00462-7. Epub 2022 Mar 16.
7
Omicron variant Spike-specific antibody binding and Fc activity are preserved in recipients of mRNA or inactivated COVID-19 vaccines.奥密克戎变异株 Spike 特异性抗体结合和 Fc 活性在接受 mRNA 或新冠灭活疫苗接种者中得到保持。
Sci Transl Med. 2022 Apr 27;14(642):eabn9243. doi: 10.1126/scitranslmed.abn9243.
8
Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study.美国奥密克戎、德尔塔和阿尔法 SARS-CoV-2 变异株的 mRNA 疫苗对新冠病毒的临床严重程度和有效性:前瞻性观察研究。
BMJ. 2022 Mar 9;376:e069761. doi: 10.1136/bmj-2021-069761.
9
SARS-CoV-2 breakthrough infections elicit potent, broad, and durable neutralizing antibody responses.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)突破性感染引发强效、广泛且持久的中和抗体反应。
Cell. 2022 Mar 3;185(5):872-880.e3. doi: 10.1016/j.cell.2022.01.011. Epub 2022 Jan 20.
10
T cell responses to SARS-CoV-2 spike cross-recognize Omicron.T 细胞对 SARS-CoV-2 刺突蛋白的交叉识别可识别奥密克戎。
Nature. 2022 Mar;603(7901):488-492. doi: 10.1038/s41586-022-04460-3. Epub 2022 Jan 31.